F3: Tissue factor
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Initiates blood coagulation by forming a complex with circulating factor VII or VIIa.
- Drugs that act on it: 1
- Approved: 1
- In phases 1 to 3: 0
- Sponsors: 1
Who Is On It, and How Far Along
Every drug ChEMBL records acting on F3, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody-drug conjugate
The Landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.| Drug | Furthest stage | Sponsor | Modality | Action | Mechanism | Open trials | Warnings |
|---|---|---|---|---|---|---|---|
| Tisotumab vedotin | Approved | Pfizer | Antibody-drug conjugate | Binding agent | Coagulation factor III binding agent | 4 | Boxed warning |
Open Trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 4 in all, from ClinicalTrials.gov.| Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva | Tisotumab vedotin | Phase 2 | Not yet recruiting | GOG Foundation | 2026-06-29 |
| Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer | Tisotumab vedotin | Phase 4 | Recruiting | Pfizer | 2025-05-01 |
| A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) | Tisotumab vedotin | Phase 3 | Active, not recruiting | Merck Sharp & Dohme LLC | 2024-06-14 |
| Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors | Tisotumab vedotin | Phase 2 | Active, not recruiting | Seagen, a wholly owned subsidiary of Pfizer | 2018-04-02 |
Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Cervical cancer
- 0.56
- Cancer
- 0.38
- Neoplasm
- 0.38
- Spontaneous coronary artery dissection
- 0.26
- Placental abruption
- 0.26
- Ovarian cancer
- 0.10
- Head and neck squamous cell carcinoma
- 0.07
- Non-small cell squamous lung carcinoma
- 0.07
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4081, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P13726, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets